FDA Application for Orphan Drug Designation , PAA, MPL, page-81

Why does it have to be hyperbolic extremisms?

The non hyperbole reality is that management never met a single timeline or delivery target, always communicated terribly and often inaccurately, and have not only not delivered an ounce of shareholder value, they have in fact eroded shareholder value. This can all be pointed to in numbers of examples.

So, because very PAA experienced shareholders are sceptical about current plans (rightly so), you accuse them of believing it is an elaborate con. A little disingenuous and takes away from objective discussion. You know you can constructively question and critique actions of the company or specific people, and still be a 'believer'.

Anyway, the ball is in the court of our new CEO who by all accounts is making a concerted effort to right the wrongs. Remember people he will have a legacy to overturn. All the dross and garbage left by the BOD will slowly need to be worked through.

Has anyone emailed MT and asked why it appears to be a long timeframe for results, when presumably we have been collating and interpreting data through each cohort....how does this fit with the statement of 'interim analysis to expedite the trial'? I'd say the latter is more BOD BS and now MT lives with that legacy.